Free Trial
NASDAQ:QTTB

Q32 Bio Q2 2026 Earnings Results & Report

Q32 Bio logo
$8.71 -0.11 (-1.25%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$8.72 +0.01 (+0.11%)
As of 11/13/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Q32 Bio beat analyst earnings expectations in its Q2 2026 results, released August 5, 2026. The company reported EPS of -$0.44 versus the -$0.46 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Q32 Bio EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.46
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
8 of last 8 quarters

Q32 Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
$750 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Q32 Bio Q2 2026 Earnings FAQ

Q32 Bio (NASDAQ:QTTB) reported earnings of -$0.44 per share for Q2 2026, beating the consensus estimate of -$0.46. The report was announced on Wednesday, August 5, 2026.

Q32 Bio Earnings Headlines

I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
Jefferies Keeps Their Buy Rating on Q32 Bio (QTTB)
See More Q32 Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Q32 Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Q32 Bio and other key companies, straight to your email.

About Q32 Bio

Q32 Bio (NASDAQ:QTTB) is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms.

The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.

Q32 Bio became a publicly traded company in 2024 through a business combination with Homology Medicines. The combined company retained the Q32 Bio name and trades on the Nasdaq under the symbol QTTB.

View Q32 Bio Profile